Rothschild & CO Asset Management Us Inc. Vertex Pharmaceuticals Inc Transaction History

Rothschild & CO Asset Management Us Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 09, 2021	SELL	$181.39 - $202.99 $2.85 Million - $3.18 Million	-15,686 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $245,424 - $289,419	-1,309 Reduced 7.7%	15,686 $3.16 Million
Q1 2021 May 14, 2021	SELL	$207.02 - $241.31 $151,952 - $177,121	-734 Reduced 4.14%	16,995 $3.65 Million
Q4 2020 Feb 08, 2021	BUY	$207.01 - $276.09 $246,548 - $328,823	1,191 Added 7.2%	17,729 $4.19 Million
Q3 2020 Nov 09, 2020	SELL	$255.65 - $303.1 $7.14 Million - $8.47 Million	-27,938 Reduced 62.82%	16,538 $4.5 Million
Q2 2020 Aug 10, 2020	SELL	$225.48 - $295.8 $4.51 Million - $5.91 Million	-19,983 Reduced 31.0%	44,476 $12.9 Million
Q1 2020 May 14, 2020	SELL	$199.77 - $247.81 $785,295 - $974,141	-3,931 Reduced 5.75%	64,459 $15.3 Million
Q4 2019 Feb 12, 2020	SELL	$166.71 - $223.91 $136,035 - $182,710	-816 Reduced 1.18%	68,390 $15 Million
Q3 2019 Nov 08, 2019	SELL	$166.23 - $187.09 $462,451 - $520,484	-2,782 Reduced 3.86%	69,206 $11.7 Million
Q2 2019 Jul 25, 2019	BUY	$164.61 - $190.37 $11.8 Million - $13.7 Million	71,988 New	71,988 $13.2 Million

1,707

226M

1.2M

1.59M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Rothschild & CO Asset Management Us Inc., based on Form 13F filings with the SEC.

Stay updated on Rothschild & CO Asset Management Us Inc. with notifications on news.